beta-alanine has been researched along with Acute Coronary Syndrome in 33 studies
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 8.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| " In Thrombin Receptor Antagonists for Clinical Event Reduction (TRA-CER), compared with standard care alone, bleeding complications including intracranial hemorrhage (ICH) were increased with the addition of vorapaxar, without efficacy benefit." | 4.90 | New antithrombotics for secondary prevention of acute coronary syndrome. ( Goto, S; Tomita, A, 2014) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 4.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "There are concerns regarding increased risk of acute coronary syndrome with dabigatran." | 4.90 | Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. ( Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "The novel oral anticoagulant drugs, comprising dabigatran, rivaroxaban, and apixaban, have emerged as compelling alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation, and low‑molecular‑weight heparin for thromboprophylaxis following hip and knee arthroplasty." | 4.89 | Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. ( Darvish-Kazem, S; Douketis, JD; Liew, A, 2013) |
| "The new oral agents demonstrate several advantages over traditional anticoagulants, including administration at fixed doses and no requirement for routine coagulation monitoring On the basis of phase III clinical trials, rivaroxaban, apixaban and dabigatran etexilate have been approved in many countries for the prevention of venous thromboembolism after hip and knee replacement surgery." | 4.89 | Implications of new anticoagulants in primary practice. ( Eraso, LH; Merli, GJ; Perez, A, 2013) |
| "The original RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran etexilate vs warfarin in patients with atrial fibrillation." | 4.88 | Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. ( Hernandez, AV; Uchino, K, 2012) |
| " The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication." | 4.88 | What did we learn from new oral anticoagulant treatment? ( Esmon, CT, 2012) |
| "Warfarin and heparins have been the predominant anticoagulants used until the past decade." | 2.50 | The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014) |
| "Warfarin has been the only available oral anticoagulant therapy for several decades." | 2.48 | Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. ( Khemasuwan, D; Suramaethakul, N, 2012) |
| " Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown." | 2.47 | Anticoagulating obese patients in the modern era. ( Arya, R; Patel, JP; Roberts, LN, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 33 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández, D | 1 |
| Penela, D | 1 |
| Heras, M | 1 |
| Bennaghmouch, N | 1 |
| Ten Berg, JM | 1 |
| Cove, CL | 1 |
| Hylek, EM | 1 |
| Goto, S | 1 |
| Tomita, A | 1 |
| Liew, A | 1 |
| Darvish-Kazem, S | 1 |
| Douketis, JD | 1 |
| Giglio, AF | 1 |
| Basile, E | 1 |
| Santangeli, P | 1 |
| Di Biase, L | 1 |
| Trotta, F | 1 |
| Natale, A | 1 |
| Singh, D | 1 |
| Gupta, K | 1 |
| Vacek, JL | 1 |
| Capodanno, D | 1 |
| Angiolillo, DJ | 1 |
| Loke, YK | 1 |
| Pradhan, S | 1 |
| Yeong, JK | 1 |
| Kwok, CS | 1 |
| Bassand, JP | 1 |
| Thachil, J | 1 |
| Chatterjee, S | 1 |
| Sardar, P | 1 |
| Giri, JS | 1 |
| Ghosh, J | 1 |
| Mukherjee, D | 1 |
| Pontillo, D | 1 |
| Patruno, N | 1 |
| Messori, A | 1 |
| Bultas, J | 1 |
| Oldgren, J | 1 |
| Budaj, A | 1 |
| Granger, CB | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Siegbahn, A | 1 |
| Tijssen, JG | 1 |
| Van de Werf, F | 1 |
| Wallentin, L | 1 |
| Moser, M | 1 |
| Bode, C | 1 |
| Patel, JP | 1 |
| Roberts, LN | 1 |
| Arya, R | 1 |
| Eerenberg, ES | 1 |
| van Es, J | 1 |
| Sijpkens, MK | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Redberg, RF | 1 |
| Jacobs, JM | 1 |
| Stessman, J | 1 |
| Uchino, K | 1 |
| Hernandez, AV | 1 |
| Soff, GA | 1 |
| Khemasuwan, D | 1 |
| Suramaethakul, N | 1 |
| Eikelboom, JW | 1 |
| Weitz, JI | 1 |
| Correia, LC | 1 |
| Lopes, AA | 1 |
| Kar, S | 1 |
| Bhatt, DL | 1 |
| Reed, SD | 1 |
| Costopoulos, C | 1 |
| Niespialowska-Steuden, M | 1 |
| Kukreja, N | 1 |
| Gorog, DA | 1 |
| Esmon, CT | 1 |
| Graf, L | 1 |
| Tsakiris, DA | 1 |
| Brasselet, C | 1 |
| Duval, S | 1 |
| Perez, A | 1 |
| Eraso, LH | 1 |
| Merli, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for beta-alanine and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Ben | 2012 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; C | 2013 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cor | 2014 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogr | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi | 2014 |
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibito | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Ben | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigat | 2014 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dab | 2011 |
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Incidence; | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
Novel oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine | 2013 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; B | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dr | 2012 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2013 |
1 trial available for beta-alanine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
10 other studies available for beta-alanine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Humans; M | 2015 |
Cardiovascular safety of new oral anticoagulants: re-analysis of 27 randomized trials based on Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Factor Xa Inhibitors; Humans; | 2015 |
Redemption by RE-DEEM?
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Huma | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzim | 2011 |
Important data after drug approval: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial | 2012 |
Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial | 2012 |
Anticoagulation therapy. Dabigatran and risk of myocardial infarction.
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction; | 2012 |
Dabigatran and myocardial infarction: meta-illusion?
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction; | 2012 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2013 |
[Role of new oral anticoagulants in interventional cardiology].
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzi | 2012 |